Prognostic Factors in Patients with Advanced HER2-Positive Gastric Cancer Treated with Trastuzumab-Based Chemotherapy: a Cohort Study
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Gastrointestinal Cancer"
DOI: 10.1007/s12029-022-00815-1
Abstract: Prognostic factors for the survival of patients with advanced HER2-positive gastric cancer treated with trastuzumab-based chemotherapy remain controversial. The aim of this study was to identify the clinical factors that predict prognosis in patients with… read more here.
Keywords: positive gastric; cancer; her2 positive; gastric cancer ... See more keywords
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of the National Cancer Institute"
DOI: 10.1093/jnci/djac227
Abstract: In advanced HER2-positive (HER2+) breast cancer (BC), the new antibody-drug conjugate trastuzumab deruxtecan (T-DXd) is more effective compared to trastuzumab emtansine (T-DM1). However, T-DXd can have significant toxicities, and the right treatment sequence is unknown.… read more here.
Keywords: her2dx; erbb2 mrna; advanced her2; breast cancer ... See more keywords
Abstract PS10-43: Pyrotinib in the treatment of women with advanced HER2 positive breast cancer: A multicenter, prospective, real world study
Sign Up to like & getrecommendations! Published in 2021 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs20-ps10-43
Abstract: Backgrounds: Pyrotinib (an irreversible pan-ErbB receptor tyrosine kinase inhibitor) plus capecitabine have been approved for patients with advanced HER2 positive breast cancer in China. However, the efficacy of pyrotinib in patients with different baseline characteristics… read more here.
Keywords: pyrotinib; treatment; cancer; breast cancer ... See more keywords
Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal – U-PIK Project
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Molecular Biosciences"
DOI: 10.3389/fmolb.2023.1082915
Abstract: Background: Around 40% of ER+/HER2-breast carcinomas (BC) present mutations in the PIK3CA gene. Assessment of PIK3CA mutational status is required to identify patients eligible for treatment with PI3Kα inhibitors, with alpelisib currently the only approved… read more here.
Keywords: pik project; advanced her2; pik; her2 breast ... See more keywords